Confirm histological grade
Confirm histological diagnosis and grade (LAMN vs. mucinous adenocarcinoma), which determines prognosis.
At Quenet-Torrent Institute, we are experts in treating pseudomyxoma peritonei, a rare condition that requires highly specialized surgery. We combine complete cytoreduction with HIPEC for optimal results — achieving cure rates above 80% in low-grade cases.
CONTACT SPECIALISTNeed to speak with a specialist?
Schedule your consultation with a specialist
Pseudomyxoma peritonei is a rare clinical condition characterized by progressive accumulation of mucinous material in the abdominal cavity. It usually originates from a ruptured appendicular mucinous tumor, although it can also arise from ovarian or other mucinous tumors. It is colloquially known as "jelly belly".
It is a slow-growing condition that can remain indolent for years. However, without treatment, the progressive accumulation of mucin causes compression of abdominal organs, intestinal obstruction, and nutritional deterioration.
Cytoreductive surgery with HIPEC is the treatment of choice and can achieve cure rates above 80% in low-grade cases when complete resection is achieved — making this the most favorable prognosis among all peritoneal malignancies.
This rare condition requires management in specialized centers with extensive documented experience.
Confirm histological diagnosis and grade (LAMN vs. mucinous adenocarcinoma), which determines prognosis.
Assess whether complete cytoreduction (CC0/CC1) is technically achievable.
Determine the best time for surgery based on disease burden and growth rate.
Ensure you are treated at a center with proven experience in this rare condition — volume matters significantly.
The surgeon's experience is the most important prognostic factor in pseudomyxoma peritonei.
Surgical treatment combined with HIPEC is the foundation of potentially curative management.
Removal of all visible mucinous disease and affected peritoneal surfaces — the most critical factor for cure.
Hyperthermic intraperitoneal chemotherapy to destroy microscopic residual mucinous cells.
Removal of affected organs when necessary: omentum, spleen, gallbladder, portions of bowel, ovaries.
Repeat interventions for recurrences when feasible — particularly effective in low-grade disease.
The goal is complete cytoreduction (CC-0/CC-1) to maximize long-term survival.
Specialized technology is essential in these complex and often lengthy surgeries.
Precise thermal and flow control for optimal intraperitoneal perfusion.
Detailed preoperative evaluation of disease distribution and extent.
Serial monitoring for disease follow-up and early detection of recurrence.
Specialist pathologists for accurate histological grading — critical for prognosis and treatment planning.
Quenet-Torrent Institute is a reference center for this rare condition with extensive accumulated experience in pseudomyxoma peritonei.
We specialize in treating advanced and metastatic cancer, using innovative techniques that other teams do not offer.
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
We stay up to date with the latest scientific advances, allowing us to apply innovative treatments with better results.
We have facilities equipped with the most current medical technology, allowing us to perform high-precision procedures with less impact on the body.
We care about each patient as a person. We listen, support, and guide every step of the way.
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
Answers to the most common questions about diagnosis, treatment, and prognosis.
Yes, especially in low-grade cases with complete cytoreduction. Cure rates exceed 80% at 10 years in favorable cases Outcomes depend on histology, PCI score, and completeness of cytoreduction.
Low-grade tumors (DPAM/LAMN) have a much better prognosis than high-grade ones (PMCA/mucinous adenocarcinoma). Accurate histological grading is essential before.
Cytoreductive surgery with HIPEC can last 8-14 hours depending on disease extent, with continuous adjustment based on intraoperative findings of the case.
Hospitalization is usually 10-14 days and complete recovery 2-3 months, though this may vary depending on the extent of surgery performed El equipo valora cada caso.
Repeat surgeries are possible and can be effective in controlling the disease long-term, particularly in low-grade cases where the disease grows slowly.
In specialized centers with extensive experience in pseudomyxoma, like Quenet-Torrent Institute, where hundreds of these procedures have been performed.
Complete the form and schedule your appointment to speak directly with the surgeon.